Ariadna Mendoza

Ariadna Mendoza has a strong background in clinical development and oncology research. Ariadna currently holds the position of Tislelizumab Global Clinical Development Lead - Senior Director, Solid Tumor at BeiGene since 2022. Prior to this, they worked at AstraZeneca, where they held various roles including Senior Director, Global Clinical Development - Immuno-Oncology, R&D from 2021 to 2022, Director Global Clinical Development Sci. - Immuno-Oncology, R&D from 2019 to 2021, and Medical Scientist, Assoc. Director Clinical Development - Oncology, R&D from 2017 to 2019. Before joining AstraZeneca, Ariadna worked at UCLH as an Oncology Team Leader from 2015 to 2017. Ariadna also worked at UCL Cancer Institute as a Group Leader - Cancer Therapeutics from 2013 to 2016 and as a Senior Research Associate/Senior Postdoc from 2009 to 2013. Earlier in their career, they held the position of Research Associate/Postdoctoral Fellow at University College London from 2006 to 2008. Ariadna also worked as a Postdoctoral Fellow - Oncobiomed Inc at Oncobiomed Inc & University of Chile from 2005 to 2006. Ariadna began their career as a Research and Teaching Assistant at the University of Chile from 1999 to 2001.

Ariadna Mendoza's education history includes a Bachelor of Science degree in Biochemistry from the University of Havana. Ariadna also holds a PhD in Biomedical Sciences from the University of Chile School of Medicine. Additionally, they have attended UCL, although there is no given information regarding their degree or field of study at this institution.